×
-0.0172736732570239 -0.0172736732570239 -0.0172736732570239 -0.0172736732570239 -0.0308012486992716 0.0197710718002083 -0.00104058272632663 -0.00104058272632663
Stockreport

The Female Health Company / Veru Healthcare Names Robert Getzenberg, Ph.D., as Executive Vice President of Clinical Development

FEMALE HEALTH (FHCO)  More Company Research Source: GlobeNewswire
US:NASDAQ Investor Relations: verupharma.com/investors
PDF MIAMI, April 11, 2017 (GLOBE NEWSWIRE) -- The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today announced the appointment of Robert H. Getzenberg, Ph.D., as Executive Vice President of Clinical Development.  Dr. Getzenberg will lead the clinical development of Veru’s portfolio of drugs under development, including Tamsulosin DRS (Tamsulosin HCl extended release for oral suspension) for the treatment of benign prostatic hyperplasia (BPH), MSS-722 for male infertility, APP-944 for hot flashes in men who are on hormonal therapies for advanced prostate cancer, and APP-111 for prostate, ovarian and breast cancers. “Robert is eminently qualified to lead our product development efforts,” said Mitchell Steiner, M.D., President and Chief Executive Officer of The Female Health Company / Veru Healthcare.  “He is a highly regarded pharmaceutical executive who also has made significant contributions as a scientific researcher, investigator and tenured professor in the worlds of urolo [Read more]

IMPACT SNAPSHOT EVENT TIME: FHCO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
FHCO alerts
from News Quantified
Opt-in for
FHCO alerts

from News Quantified
Opt-in for
FHCO alerts

from News Quantified